Status | Study |
NOT_YET_RECRUITING |
Study Name: Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)� Condition: Date: 2023-06-02 Interventions: Patients will receive VS-01 intraperitoneally on four consecutive days on top of SOC |
NOT_YET_RECRUITING |
Study Name: Identification and Verification of Neutrophil Extracellular Trap Net Related Markers in Acute-on-chronic Liver Failure Condition: Date: 2023-05-29 |
Recruiting |
Study Name: To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF). Condition: Acute-On-Chronic Liver Failure Date: 2017-04-20 Interventions: Drug: Standard Medical Therapy |
Not yet recruiting |
Study Name: The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF. Condition: Liver Failure Date: 2017-02-23 Interventions: Drug: Thymosin-α1 1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a w |
Recruiting |
Study Name: Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study Condition: Liver Cirrhosis With Acute Decompensation Date: 2017-02-13 Interventions: Other: Observation protocol The whole cohort will be followed for 3 months, while Group 1 will be follow |
Not yet recruiting |
Study Name: Safety and Performance Trial of DIALIVE Liver Dialysis Device in Acute On Chronic Liver Failure Patients Condition: Acute on Chronic Liver Failure Date: 2017-01-18 Interventions: Device: DIALIVE Liver Dialysis Device ACLF patients will receive dialysis treatment for 8-12 hrs/day and |
Not yet recruiting |
Study Name: Prostaglandin E2 Predicts the Outcome of Acute-on-chronic Liver Failure Condition: Acute-On-Chronic Liver Failure Cirrhosis and Chronic Liver Dise Date: 2016-11-14 |
Not yet recruiting |
Study Name: Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF Condition: Acute-On-Chronic Liver Failure Date: 2016-10-13 Interventions: Biological: HepaStem |
Recruiting |
Study Name: Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction Condition: Cirrhosis Liver Failure Date: 2016-07-13 Interventions: Drug: Human derived Transfer factor |
Not yet recruiting |
Study Name: UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver Failure Condition: Liver Failure Date: 2016-05-27 Interventions: Drug: umbilical cord blood mesenchymal stem cells |